Physician profile
Theodore Daly
NPI 1518965441
$480,033.73
in general payments reported to CMS, 2019-2025
37 companies · $39K in 2025
The $39K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $46K · 2021: $39K · 2022: $90K · 2023: $95K · 2024: $128K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $195K · Consulting Fee: $31K · Travel and Lodging: $18K · Food and Beverage: $13K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,960 · Education: $610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $194,980.00 |
| Consulting Fee | $30,970.00 |
| Travel and Lodging | $18,226.47 |
| Food and Beverage | $13,262.49 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,960.00 |
| Education | $610.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $128,082.66 | 2019-2025 | |
| Lilly USA, LLC | $120,268.73 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Amgen INC. | $113,393.27 | 2020-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39,680.39 | 2022-2024 | Spevigo |
| Celgene Corporation | $20,741.56 | 2019 | |
| Abbvie INC. | $18,758.08 | 2019-2025 | Rinvoq, Ubrelvy |
| E.R. Squibb & Sons, L.L.C. | $12,457.59 | 2019-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $5,677.97 | 2021-2025 | Winlevi, Absorica Ld |
| Arcutis Biotherapeutics, INC. | $4,466.11 | 2023-2025 | Zoryve |
| Genzyme Corporation | $3,656.10 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,910.95 | 2019-2023 | Arazlo, Duobrii |
| Regeneron Healthcare Solutions, INC. | $1,676.28 | 2019-2025 | Dupixent |
| Helsinn Therapeutics (U.S.), INC. | $1,455.00 | 2019 | |
| Dermira, INC. | $1,243.93 | 2019-2021 | |
| Janssen Biotech, INC. | $1,145.39 | 2019-2025 | Tremfya, Simponi, Stelara |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $792.83 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $545.63 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Leo Pharma INC. | $531.26 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $499.44 | 2019-2025 | |
| Medimetriks Pharmaceuticals, INC. | $481.17 | 2019-2021 | |
| Almirall LLC | $442.36 | 2019-2025 | Klisyri, Seysara |
| Journey Medical Corporation | $441.40 | 2019-2025 | |
| Ucb, INC. | $342.00 | 2019-2025 | Bimzelx, Cimzia |
| Sanofi-Aventis U.S. LLC | $216.76 | 2019-2021 | |
| Biofrontera INC. | $206.11 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Dermavant Sciences, INC. | $190.77 | 2023-2024 | Vtama |
| Allergan, INC. | $127.00 | 2019 | |
| Merz North America, INC. | $125.44 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $125.16 | 2019-2023 | |
| Janssen Scientific Affairs, LLC | $72.84 | 2023 | Tremfya |
| Sandoz INC. | $61.58 | 2019-2020 | |
| Epi Health, LLC | $54.73 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $45.00 | 2019 | |
| Botanix Sb INC | $39.46 | 2025 | Sofdra |
| Organon LLC | $32.10 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $23.70 | 2024 | Ycanth |
| Endo Pharmaceuticals INC. | $22.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Daly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.